What is William Blair’s Forecast for TARS FY2024 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Research analysts at William Blair boosted their FY2024 EPS estimates for Tarsus Pharmaceuticals in a research report issued on Thursday, November 14th. William Blair analyst L. Hanbury-Brown now expects that the company will earn ($3.26) per share for the year, up from their previous estimate of ($3.72). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.41) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q4 2024 earnings at ($0.77) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at $0.22 EPS and FY2025 earnings at ($0.96) EPS.

Other analysts have also recently issued reports about the stock. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock opened at $44.63 on Monday. The company has a current ratio of 5.42, a quick ratio of 6.99 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -11.71 and a beta of 1.00. Tarsus Pharmaceuticals has a 1-year low of $15.60 and a 1-year high of $52.99. The firm’s 50-day moving average price is $38.11 and its two-hundred day moving average price is $32.60.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently modified their holdings of TARS. Quest Partners LLC acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at approximately $61,000. Canada Pension Plan Investment Board acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after buying an additional 1,530 shares during the period. FMR LLC lifted its holdings in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after buying an additional 3,537 shares during the period. Finally, Dark Forest Capital Management LP acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at approximately $202,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.